This test aims to be a predictive test for breast and ovarian cancer. In the 30-50% of these cases the cause is an alteration of two main genes: BRCA1 and BRCA2.

Identifies variants in the BRCA1 and BRCA2 genes.

Variants on these genes are related to an increased risk of developing breast cancer and or ovarian/falloppian tubes cancer. Breast cancer is the most common cancer in women, with an incidence of 1 every 8 women (12%) of which 5 -10% shows an hereditary predisposition.

The test consists in a blood test, in the extraction of genomic DNA and in the analysis of the full coding sequence and related exon/intron junctions of the BRCA1 and BRCA2 genes using NGS technology. The test also allows the analysis of the copy nubers variations by quantitative dosage of genomic DNA through the use of molecular probes.

Results in 30 working days.

Analitical sensitivity, specificity and accuracy > 99%.